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Background: Diabetic nephropathy (DN) has become one of the most common causes of end-stage renal disease
(ESRD) in many countries, such as 44.5% in Taiwan. Previous studies have shown that there is a genetic component
to ESRD. Studies attempting to determine which genetic variants are related to DN in Han Chinese are limited. A
case–control study was conducted to identify DN susceptibility variants in Han Chinese patients with type 2 diabetes.
Results: We included 574 unrelated type 2 diabetes patients (217 DN cases and 357 controls), who were genotyped
using Illumina HumanHap550-Duo BeadChip. In single-SNP association tests, the SNPs rs11647932, rs11645214, and
rs6499323 located at 16q22.1 under the additive-effect disease model were significantly associated with an approximately
2-fold increased risk of DN. In haplotype association tests, identified haplotypes located in the chromosome
16q22.1 region (containing ST3GAL2, COG4, SF3B3, and IL34 genes) raised DN risk. The strongest association was found
with haplotype rs2288491-rs4985534-rs11645214 (C-C-G) (adjusted odds ratio [AOR] 1.93, 95% confidence interval [CI]
1.83-2.03, p = 6.25 × 10−7), followed by haplotype rs8052125-rs2288491-rs4985534-rs11645214 (G-C-C-G) (AOR 1.92,
95% CI 1.82-2.02, p = 6.56 × 10−7), and haplotype rs2303792-rs8052125-rs2288491-rs4985534-rs11645214 (A-G-C-C-G)
(AOR 1.91, 95% CI 1.81-2.01, p = 1.15 × 10−6).
Conclusions: Our results demonstrate that the novel SNPs and haplotypes located at the 16q22.1 region may involve
in the biological pathways of DN in Han Chinese patients with type 2 diabetes. This study can provide new insights
into the etiology of DN.
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Diabetic nephropathy (DN) has become one of the most
common causes of end-stage renal disease (ESRD) in many
countries. In Taiwan, diabetes accounted for 44.5% of all
new cases of ESRD [1], and more than 99% diabetes pa-
tients were with type 2 diabetes [2]. Diabetic ESRD patients
had worse survival than non-diabetic ESRD patients [3].
It has been reported that genetic predisposition is one of
the main risk factors for the development of DN [4]. Nu-
merous familial aggregation studies have suggested that* Correspondence: tcli@mail.cmu.edu.tw; d0704@mail.cmuh.org.tw
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unless otherwise stated.genetic susceptibility plays an important role in the devel-
opment and progression of DN [5,6]. Epidemiologic stud-
ies have shown that 35% of patients with diabetes develop
nephropathy, irrespective of glycemic control [7,8].
Mooyaart et al. performed a meta-analysis to evaluate the
pooled effect of each genetic variant reproducibly associated
with DN [9]. They reported that 21 of 34 replicated genetic
variants remained significantly associated with DN. These 34
variants were in or near the following genes: ACE, ELMO1,
PPARG, etc. Recently, several genome-wide association stud-
ies (GWASs) have attempted to detect genetic variants asso-
ciated with the risk of DN or diabetic ESRD in those of
Japanese [10], Pima Indian [11], and African American [12]
with type 2 diabetes, as well as European ancestry [13,14]
with type 1 diabetes.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ants are related to DN in Han Chinese patients with type
2 diabetes are limited. In the present genetic association
study, a case–control study was carried out to identify
DN susceptibility variants in Han Chinese patients with




Individuals with type 2 diabetes and aged over 20 years
were recruited using the American Diabetes Association
(ICD-9-CM, Diagnosis code 250) criteria for diagnosis of
type 2 diabetes. Individuals with type 1 diabetes, gesta-
tional diabetes, and maturity-onset diabetes of the young
were excluded. The dataset used is part of the whole data-
set for the published paper titled “A Genome-wide Associ-
ation Study Identifies Susceptibility Variants for Type 2
Diabetes in Han Chinese” [15]. A total of 995 type 2 dia-
betes subjects recruited from China Medical University
Hospital were included in the current study. All patients
with type 2 diabetes were of Han Chinese origin, including
Minnan, Hakka, and Mainland Chinese. Individuals with
significant aboriginal ancestry were excluded by using self-
administered questionnaires with six items regarding the
ancestral origin of their parents and grandparents.
Chronic kidney disease (CKD) was determined by esti-
mated glomerular filtration rate (eGFR) and urine protein.
Diabetic patients with eGFR <60 mL/min/1.73 m2 or with
proteinuria determined by a spot urine dipstick of >1+
were defined as DN cases. A total of 217 DN cases were
eligible for the study. To increase comparability between
DN cases and controls, 357 controls were randomly
selected based on frequency-matching of their age and
durations of diabetes. This study was approved by the
Human Research Committee of China Medical University
Hospital. All patients signed informed consent forms.
Measurements
Blood samples were collected in the morning after a 12-h
overnight fast and were sent for analysis within 4-h of col-
lection. Spot morning urine samples were collected. Triglyc-
erides, total cholesterol, high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), cre-
atinine, blood urea nitrogen (BUN), and uric acid were
measured by a biochemical autoanalyser (Beckman
Coulter, Synchron LX20, Fullerton, CA, USA). Renal
function was evaluated by eGFR, which was estimated by
using the Modification of Diet in Renal Disease Study
equation for Taiwanese: eGFR (ml/min/1.73 m2) = 175 ×
(serum creatinine (mg/dL)−1.154 × (age)−0.203 × (0.742 if fe-
male) × 0.945 [16]. We also used the Chronic Kidney Dis-
ease Epidemiology Collaboration equation to obtain eGFR
[17]. The proportions of eGFR <60 mL/min/1.73 m2 byusing above two equations were similar. A spot urine dip-
stick test was used for detecting proteinuria. Patients with a
positive dipstick test (>1+) were classified as with protein-
uria [18]. The sociodemographic and lifestyle characteristics
and the self-reported health status for each subject were re-
corded using self-administered questionnaires.
Genotyping and quality control
Genomic DNA from peripheral blood was prepared using
the Puregene DNA isolation kit (Gentra Systems,
Minneapolis, MN, USA). Our samples were genotyped
using Illumina HumanHap550-Duo BeadChip, which
was performed by deCODE Genetics (Reykjavík,
Iceland). Genotypes were called using the standard pro-
cedure in BeadStudio (Illumina, Inc., San Diego, CA,
USA), with the default parameters recommended by the
platform manufacturer. The genotyping quality control
procedures used to identify and remove poor-quality
data were described previously [15]. Individual SNPs
were excluded if they had a total call rate <95% across
all individuals, a minor allele frequency <5% and a total
call rate <99%, or had significant deviation from Hardy-
Weinberg disequilibrium (p-value <10−7) in these subjects.
Further details of genotyping quality control procedures
are available in the published study [15]. After SNPs qual-
ity control, 429,018 SNPs were used and their total call
rate was 99.9%. We also examined population stratifica-
tion by using multidimensional scaling (MDS) analysis
as implemented in PLINK. The results of MDS analysis
showed that there was no evidence for population
stratification.
Statistical analysis
Demographic and clinical characteristics of study subjects
were examined, including sex, age, diabetes-related variables,
behaviors, biochemical variables, and history of diseases.
Continuous variables are reported as mean ± standard devi-
ation (SD), and categorical variables are reported as number
and percentage. Two-sample t tests and Chi-square tests
were used for the bivariate analyses. Because the distribution
of the triglycerides was skewed, the data were normalized
using a natural log-transformation, and the geometric
mean ± SD was calculated. To identify the DN susceptibil-
ity variants, single-SNP association tests using Cochran-
Armitage trend test were performed. Then, multiple
logistic regression analysis using an additive-effect disease
model (an ordinal genotype model: 0, 1 and 2 of a minor
allele) was performed for each SNP with adjustment of the
subject's sex, age, BMI, and durations of diabetes. The
Bonferroni correction was used to adjust for multiple com-
parisons. P-value less than 10−4, association was considered
to be statistically significant. According to previously pub-
lished studies, as well as the results of single-SNP associ-
ation tests and the Manhattan plot in our current study,
Liao et al. BMC Genetics 2014, 15:113 Page 3 of 11
http://www.biomedcentral.com/1471-2156/15/113potential susceptibility regions for DN were selected to
perform haplotype analysis. In haplotype-based association
analysis, the sliding window approach was adopted to de-
tect haplotype effects. The window sizes of 3-SNP, 4-SNP,
and 5-SNP haplotypes were used. Each haplotype with a
frequency of >0.05 in this population was analyzed. Odds
ratios (ORs) and their corresponding 95% confidence inter-
vals (CIs) were calculated to estimate the effect sizes of the
identified SNPs and haplotypes. In addition, the linkage
disequilibrium (LD) structures of the identified contiguous
SNPs were examined. Pairwise LD was measured by the r2
statistic. For power calculation of our case–control study
(217 DN cases and 357 controls), Quanto software [19]
was used. Under an additive effect disease model with a
prevalence of 10% for DN (from our dataset), given a gen-
etic relative risk of 1.85 and a disease allele frequency of
0.25-0.45, the power of our study was 0.76-0.86 at an alpha
level of 10−4. All analyses were carried out using Haploview
(v4.2) [20], PLINK (v1.07) (pngu.mgh.harvard.edu/purcell/
plink) [21], and SAS (v9.3, SAS Institute Inc, Cary, NC,
USA) software. The regional plot was plotted from the
LocusZoom, a web-based plotting tool (csg.sph.umich.edu/
locuszoom) [22]. The in silico prediction tool is-rSNP was
used to predict potential regulatory SNPs (rSNPs) [23].
Results
Demographic and clinical characteristics of study samples
A total of 574 type 2 diabetes study participants, com-
prising 217 cases of DN and 357 type 2 diabetes patients
without DN controls, were included in the analysis.
Table 1 shows the sociodemographic factors, diabetes-
related variables, lifestyle behaviors, biochemical vari-
ables, and history of diseases according to DN status.
The mean age of the participants was about 62 years for
both groups and their mean HbA1c at enrollment was
8.2 ± 1.7% for the cases and 7.9 ± 1.4% for the controls.
The mean durations of diabetes were 11.1 ± 7.7 years for
the cases and 10.2 ± 7.2 years for the controls. Compared
with the controls, DN cases had higher mean BMI, tri-
glycerides, creatinine, uric acid, BUN, and prevalence of
hypertension and heart disease.
The graphical summary plot and single-SNP association
tests
The graphical summary plot of DN in single-SNP associ-
ation analysis under additive-effect disease model is shown
in Figure 1. There were four SNPs with p-value <10−5 (above
the red line), including rs10963767 (intron; ADAMTSL1
gene; 9p21.3), rs2058289 (intergenic; 12q24.3), rs11645214
(3’ UTR; SF3B3 gene; 16q22.1), and rs6499323 (intron;
IL34; 16q22.1). Furthermore, two signals with p-value <10−4
were observed, indicating the SNPs around this areas
may be potential susceptibility variants for DN; one sig-
nal (rs876142, rs9928626, rs11647932, rs11645214, andrs6499323) was on chromosome 16 (16q21-16q22.1
regions) and the other (rs1028555, rs4815800, rs6065925,
rs6131015, rs4812997, rs6074024, rs6127983, rs182784,
rs1885580, rs7273764, rs6127999, rs6014975, rs4811839,
rs6025517, and rs2426712) was on chromosome 20 (20p12.3
and 20q13.1-20q13.3 regions). Among these 15 SNPs on
chromosome 20, only SNPs rs6127983 and rs182784 (intron;
BMP7 gene; 20q13.3) and SNPs rs4811839 and rs6025517
(intron; RAE1 gene; 20q13.3) were inside of genes. A previ-
ous study reviewed in a meta-analysis by Mooyaart et al.
showed that the Hp 1/2 variant in the HP gene (located at
16q22.2) was associated with DN. Therefore, a total of 383
genotyped SNPs at the 16q22.1-16q22.2 regions were
selected for this study. Significant SNPs (p-value <10−4)
identified from single-SNP association analysis, along
with the other 8 SNPs identified from haplotype associ-
ation analysis, are presented in Table 2. The SNP with
the lowest p-value (6.25 × 10−7) was rs11645214 located
on chromosome 16q22.1. This SNP, with a higher risk of
DN (adjusted odds ratio [AOR] 1.94, 95% confidence inter-
val [CI] 1.49-2.51), is inside the SF3B3 gene (Additional
file 1: Figure S1). Two other SNPs that showed a sig-
nificant or borderline significant association with DN,
each with an additive-effect, were rs6499323 (IL34) and
rs11647932 (ST3GAL2) on chromosome 16q22.1 (Additional
file 1: Figure S1). No significant variants were detected
for DN at the 16q22.2 region.
The LD structures and haplotypic association tests
Pairwise LDs among the 11 SNPs located at 16q22.1 re-
gion are shown in Figure 2. SNPs rs8062183 in ST3GAL2,
rs2303792 and rs8052125 in COG4, and rs2288491 in
SF3B3 were in strong LD with each other (r2 > 0.94). SNP
rs11645214 in SF3B3 was highly in LD with rs6499323 in
IL34 (r2 = 0.92). Nevertheless, SNP rs11647932 and other
SNPs were not in LD with r2 values ranging from 0.04 to
0.30.
Genotyped SNPs at the 16q22.1-16q22.2 regions were
selected for the haplotypic association tests in this study.
The window sizes of 3-SNP, 4-SNP, and 5-SNP haplotypes
were used to detect haplotype effects on DN, and a fre-
quency of >0.05 was analyzed. The haplotypes with a p-
value <10−4 are listed in Table 3. There were 4, 3, and 4
haplotypes with p-value <10−5 in window size of 3-SNP, 4-
SNP, and 5-SNP significantly associated with DN in this
sample, respectively, after adjusted for sex, age, BMI,
and durations of diabetes. In particular, haplotype
rs2288491-rs4985534-rs11645214 (C-C-G) (AOR 1.93,
95% CI 1.83-2.03, p = 6.25 × 10−7), haplotype rs8052125-
rs2288491-rs4985534-rs11645214 (G-C-C-G) (AOR 1.92,
95% CI 1.82-2.02, p = 6.56 × 10−7), and haplotype rs2303792-
rs8052125-rs2288491-rs4985534-rs11645214 (A-G-C-C-G)
(AOR 1.91, 95% CI 1.81-2.01, p = 1.15 × 10−6) seem to
be associated with a higher risk of DN. All haplotypes
Table 1 Demographic and clinical characteristics of study samples
Characteristics Cases (n = 217) Controls (n = 357) p-value
Sociodemographic factors
Male 108 (49.8) 170 (47.6) 0.617
Age at enrollment (years) 62.9 ± 9.1 62.6 ± 9.2 0.673
Diabetes-related variables
Age at onset of type 2 diabetes (years) 51.8 ± 9.4 52.4 ± 9.1 0.463
Durations of diabetes (years) 11.1 ± 7.7 10.2 ± 7.2 0.154
HbA1c at enrollment (%) 8.2 ± 1.7 7.9 ± 1.4 0.043
BMI (kg/m2) 26.0 ± 3.9 24.7 ± 3.5 < 0.001
Lifestyle behaviors
Regular exercise 123 (56.7) 260 (72.8) < 0.001
Smoking status 0.926
Ever 33 (15.2) 52 (14.6)
Yes 36 (16.6) 56 (15.7)
Alcohol drinking 0.032
Ever 20 (9.2) 14 (3.9)
Yes 34 (15.7) 63 (17.7)
Biochemical variables
Triglycerides (mg/dL)a 156.8 ± 1.8 131.1 ± 1.8 < 0.001
Total cholesterol (mg/dL) 192.8 ± 53.8 185.9 ± 37.2 0.099
HDL-C (mg/dL) 47.0 ± 13.9 49.4 ± 13.7 0.042
LDL-C (mg/dL) 118.1 ± 42.2 117.5 ± 33.3 0.856
Creatinine (mg/dL) 1.4 ± 1.1 0.7 ± 0.2 < 0.001
Uric Acid (mg/dL) 7.4 ± 1.9 5.9 ± 1.4 < 0.001
BUN (mg/dL) 24.9 ± 12.7 15.4 ± 4.0 < 0.001
Proteinuria 125 (57.9) 0 (0.0) < 0.001
eGFR <60 ml/min/1.73 m2 149 (68.7) 0 (0.0) < 0.001
History of diseases
Hypertension 140 (64.5) 156 (43.7) < 0.001
Heart disease 67 (30.9) 64 (17.9) < 0.001
Stroke 17 (7.8) 15 (4.2) 0.066
Diabetic retinopathy 41 (18.9) 41 (11.5) 0.014
Diabetic foot 9 (4.2) 5 (1.4) 0.039
Data were presented as mean ± SD for continuous variables or n (%) for categorical variables. eGFR: estimated glomerular filtration rate; BUN: blood urea nitrogen.
aGeometric mean was presented.
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that exerted significant associations with DN in single-
SNP association analysis.
Discussion
There is very limited evidence that any of genetic vari-
ants contribute to DN in Han Chinese populations. In
this study, we expand on the previous investigation by
Tsai et al. [15], which described compelling evidence of
an association of type 2 diabetes with polymorphisms.
We found that p-values of four SNPs were less than 10−5
in the Figure 1, and two signals, i.e. p-value <10−4, wereobserved. We identified 11 SNPs in four loci located in
16q22.1 that were associated with DN in a Han Chinese
population. As a consequence, we were able to identify
novel loci specifically associated with DN. Two SNPs of
two loci with p-values in the 10−5 to 10−7 range were iden-
tified for DN. These include SNPs rs11645214 (SF3B3)
and rs6499323 (IL34), with about a 2-fold increased risk of
DN. In the haplotype association analysis, 15 haplotypes,
including these three SNPs (rs11647932, rs11645214, and
rs6499323), carried an approximately 2-fold increased risk
of DN, which further confirmed the findings of the single-
SNP association tests.
Figure 1 Graphical summary of DN in single-SNP association analysis under additive-effect disease model.
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ferent racial groups have been conducted [10-14]. These
studies showed that different polymorphisms in or near
genes may be related to DN susceptibility, for example, in-
tron 18 + 9170 (ELMO1) in Japanese with type 2 diabetes
[10]; rs2648875 (PVT1) and rs2720709 (PVT1) in Pima
Indians with type 2 diabetes [11]; rs6930576 (SASH1),
rs7769051 (near RPS12), rs2358944 (MSRB3~HMGA2),
rs2106294 (LIMK2), rs4820043 (LIMK2), rs7735506
(AUH), and rs5749286 (SFI1) in African Americans with
type 2 diabetes [12]; rs10868025 (near FRMD3), rs1888747
(near FRMD3), rs451041 (CARS), and rs739401 (CARS)
in European ancestry with type 1 diabetes [13]; and
rs12437854 (RGMA ~MCTP2), rs7583877 (AFF3), and
rs7588550 (ERBB4) in European ancestry with type 1
diabetes [14] (Additional file 1: Table S1). The suscepti-
bility variants for DN varied widely among different
population groups, which may be due to ethnic differ-
ences and genetic backgrounds. In this study, we found
that polymorphisms in the ST3GAL2, COG4, SF3B3,
IL34, and BMP7 genes may contribute to DN suscepti-
bility in Han Chinese residing in Taiwan. In previous
candidate gene studies, these genes have not been reported
for DN in Han Chinese (Additional file 1: Table S2). The
proportions of minor alleles of SNPs rs11647932 and
rs6499323 among Taiwanese (14% and 34%, respectively)
were similar to those of Han Chinese in China (CHB: 14%
and 36%), but higher than those of Japanese (JPT: 12%
and 28%), Europeans (CEU: 12% and 20%), and Africans
(YRI: 0% and 12%) [24].Many plausible mechanisms have been hypothesized to
be involved in the association between DN and identified
SNPs. First, the protein encoded by the ST3GAL2 gene
mapped on chromosome 16q22.1 catalyzes the transfer of
sialic acid from CMP-sialic acid to galactose-containing
substrates [25]. Sialic acid is one of the inflammatory bio-
markers of the acute-phase response and is a possible risk
factor for cardiovascular disease [26]. Sialic acid was
synthesized as a result of cytokines released by inflamma-
tory cells and damaged endothelia due to angiopathy-
associated tissue injury [26]. This cytokine response could
directly result in vasculopathy in diabetes through athero-
sclerosis [26]. Moreover, cross-sectional and longitudinal
studies have shown that elevated serum sialic acid concen-
trations are related to diabetic microvascular complica-
tions (including DN) in type 2 diabetes [27,28] or type 1
diabetes [29,30]. A strong association between increased
serum sialic acid concentrations and macrovascular com-
plications (coronary heart disease; CHD) in type 2 diabetes
was also observed [31]. In addition, a 7-year prospective
cohort study revealed that a raised serum sialic acid con-
centration is associated with CHD in type 1 diabetes [32].
Second, the protein encoded by the COG4 (a compo-
nent of oligomeric golgi complex 4) gene, including
COG4, is critical for the structure and function of the
Golgi apparatus and can influence intracellular membrane
trafficking, including the addition and processing of car-
bohydrates (glycosylation) in the rough endoplasmic
reticulum and Golgi [33,34]. Mutations in COG4 may lead
to abnormal functioning in the Golgi apparatus, resulting
Table 2 Single-SNP association analysis for DN at the 16q22.1-16q22.2 regions under the additive modela
SNP Minor (major) allele MAF (Cases) MAF (Controls) Gene Location Crude OR (95% CI) p-valueb Adjusted OR (95% CI) p -valuec
rs4985526 T (C) 0.26 0.33 ST3GAL2 intron 0.71 (0.55-0.93) 1.26E-02 0.72 (0.55-0.95) 1.79E-02
rs11647932 T (C) 0.24 0.14 ST3GAL2 intron 1.84 (1.36-2.50) 6.39E-05 1.82 (1.34-2.48) 1.37E-04
rs8062183 A (G) 0.35 0.45 ST3GAL2 near-gene-5 0.68 (0.53-0.87) 2.19E-03 0.69 (0.53-0.88) 3.55E-03
rs2303792 G (A) 0.35 0.44 COG4 intron 0.68 (0.53-0.88) 2.54E-03 0.69 (0.53-0.89) 4.05E-03
rs8052125 T (G) 0.35 0.44 COG4 intron 0.67 (0.52-0.86) 1.68E-03 0.68 (0.52-0.87) 2.79E-03
rs2288491 T (C) 0.35 0.44 SF3B3 intron 0.68 (0.53-0.88) 2.62E-03 0.69 (0.53-0.89) 3.91E-03
rs4985534 T (C) 0.24 0.31 SF3B3 intron 0.69 (0.53-0.90) 6.91E-03 0.69 (0.52-0.91) 8.23E-03
rs11645214 G (A) 0.49 0.33 SF3B3 3' UTR 1.92 (1.49-2.48) 3.07E-07 1.94 (1.49-2.51) 6.25E-07
rs6499323 G (A) 0.47 0.34 IL34 intron 1.77 (1.38-2.28) 7.24E-06 1.81 (1.40-2.35) 7.10E-06
rs7197333 C (T) 0.16 0.21 IL34 intron 0.71 (0.52-0.97) 2.86E-02 0.69 (0.51-0.95) 2.20E-02
rs1006985 C (T) 0.44 0.50 IL34 intron 0.76 (0.60-0.97) 2.85E-02 0.75 (0.58-0.96) 2.18E-02
MAF: minor allele frequency.
aSignificant SNPs (p-value <10−4) identified from single-SNP association analysis, along with the other 8 SNPs identified from haplotype association analysis, are presented.
bp-value from Chi-square test (Cochran-Armitage trend test).


















Figure 2 Pairwise linkage disequilibrium (LD) among the 11 SNPs located at 16q22.1 region. Pairwise LD was measured by the r2 statistic.
An r2 value of 1 indicates a complete LD between two SNPs, and an r2 value of 0 indicates a perfect equilibrium. Lower r2 value shows a lower
degree of LD. Pairwise D’ values along with LOD scores were displayed in different colors. White indicates D’ <1 and LOD <2; blue indicate D’ = 1
and LOD <2; bright red indicate D’ = 1 and LOD ≥2; shades of pink/red indicate D’ <1 and LOD ≥2.
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plasma. Diabetes mellitus is characterized by chronic
hyperglycaemia. A number of studies have examined the
relationship of hyperglycaemia, classified according to
mean levels of HbA1c [35-37] or fasting plasma glucose
[38,39], with diabetic complications.
Third, the IL34 (interleukin 34) gene maps on
chromosome 16q22.1. Interleukin 34 is a cytokine that
promotes the differentiation and viability of monocytes
and macrophages through the colony-stimulating factor-
1 receptor (CSF1R) [40], and the causative role of macro-
phages and/or monocytes in DN has been demonstrated
by cell depletion studies in animal models [41,42]. Many
studies have shown that inflammatory cytokines such as
IL-1, IL-6, IL-18, and TNF-α are important in the patho-
genesis of diabetic microvascular complications (including
DN) [43]. Furthermore, previous studies have revealed
that cytokine gene polymorphisms such as IL-1, IL-6,
and TNF-α are related to DN [44]. Variants in IL34
may play a role in the pathogenesis of DN because of
the highly correlated cytokine network, although there
is no direct evidence for the association between IL34
gene polymorphisms and DN.
Fourth, the protein encoded by the BMP7 (bone morpho-
genetic protein 7) gene mapped on 20q13.3 is a member of
the transforming growth factor-beta (TGF-β) superfamily,
and is highly expressed in the kidney tubules and glomeruli
[45]. Previous studies showed that TGF-β cellular signalingis critical to the induction of glomerular and tubulointersti-
tial fibrosis in DN [46]. Animal studies demonstrated that
the renal BMP7 protected against DN [47], and the BMP7
partially reversed kidney hypertrophy induced by diabetes,
urine albumin excretion, restoring GFR, as well as glomeru-
lar histology toward normal [48]. McKnight et al. investi-
gated the association of BMP gene variants with DN in
White individuals with type 1 diabetes, and they reported
that the common variants in BMP2, BMP4 and BMP7
genes did not strongly influence genetic susceptibility to
DN [49]. In our study, we found that two SNPs in BMP7
gene may be susceptibility variants of DN in Han Chinese
patients with type 2 diabetes.
For predicting potential rSNPs, we used the in silico pre-
diction tool is-rSNP [23]. The is-rSNP predicted that
rs2058289, rs9928626, rs11647932, rs1028555, rs6127999,
rs6131015, rs7273764, and rs4815800 are potential rSNPs;
that is, they affect the binding affinity of a transcription
factor to the DNA (Additional file 1: Table S3). For ex-
ample, alleles of rs2058289 alter the binding affinity of
Sp4_2 (p = 0.021) and Eomes_1 (p = 0.036); alleles of
rs9928626 alter the binding affinity of LYS14 (p = 0.018),
YKL222C (p = 0.043), and YDR520C (p = 0.043); and al-
leles of rs11647932 alter the binding affinity of LM226
(p = 0.050). Furthermore, from the online Nephromine
database (www.nephromine.org), there were some evi-
dences in the literature that the expression of candi-
date genes in our study were associated with DN in
Table 3 Haplotypic association tests for DN at the 16q22.1-16q22.2 regionsa
Haplotypesb SNPs H-freq (Cases) H-freq (Controls) Crude OR (95% CI) p-valuec Adjusted OR (95% CI) p-valued
Window size of 3-SNP
H1 (C-T-G) rs4985526-rs11647932-rs8062183 0.24 0.14 1.86 (1.72-2.01) 7.36E-05 1.84 (1.70-1.99) 1.10E-04
H2 (T-G-A) rs11647932-rs8062183-rs2303792 0.24 0.14 1.85 (1.71-2.00) 7.18E-05 1.84 (1.70-1.99) 1.07E-04
H3 (C-C-G) rs2288491-rs4985534-rs11645214 0.49 0.33 1.92 (1.82-2.02) 5.40E-07 1.93 (1.83-2.03) 6.25E-07
H4 (C-G-G) rs4985534-rs11645214-rs6499323 0.47 0.33 1.86 (1.76-1.96) 2.08E-06 1.90 (1.80-2.01) 1.48E-06
H5 (G-G-T) rs11645214-rs6499323-rs7197333 0.47 0.33 1.86 (1.76-1.96) 2.08E-06 1.90 (1.80-2.01) 1.48E-06
H6 (G-T-T) rs6499323-rs7197333-rs1006985 0.39 0.27 1.73 (1.62-1.84) 4.42E-05 1.85 (1.74-1.97) 8.93E-06
Window size of 4-SNP
H7 (T-G-A-G) rs11647932-rs8062183-rs2303792-rs8052125 0.24 0.14 1.85 (1.71-2.00) 8.22E-05 1.85 (1.71-2.00) 8.04E-05
H8 (G-C-C-G) rs8052125-rs2288491-rs4985534-rs11645214 0.48 0.33 1.91 (1.81-2.01) 6.99E-07 1.92 (1.82-2.02) 6.56E-07
H9 (C-C-G-G) rs2288491-rs4985534-rs11645214-rs6499323 0.47 0.33 1.86 (1.76-1.96) 2.08E-06 1.87 (1.77-1.97) 1.76E-06
H10 (C-G-G-T) rs4985534-rs11645214-rs6499323-rs7197333 0.47 0.33 1.86 (1.76-1.96) 2.08E-06 1.87 (1.77-1.97) 1.76E-06
H11 (G-G-T-T) rs11645214-rs6499323-rs7197333-rs1006985 0.39 0.27 1.74 (1.63-1.86) 4.63E-05 1.76 (1.65-1.88) 3.16E-05
Window size of 5-SNP
H12 (A-G-C-C-G) rs2303792-rs8052125-rs2288491-rs4985534-rs11645214 0.48 0.33 1.90 (1.80-2.00) 9.62E-07 1.91 (1.81-2.01) 1.15E-06
H13 (G-C-C-G-G) rs8052125-rs2288491-rs4985534-rs11645214-rs6499323 0.47 0.33 1.86 (1.76-1.96) 2.08E-06 1.90 (1.80-2.01) 1.48E-06
H14 (C-C-G-G-T) rs2288491-rs4985534-rs11645214-rs6499323-rs7197333 0.47 0.33 1.86 (1.76-1.96) 2.08E-06 1.90 (1.80-2.01) 1.48E-06
H15 (C-G-G-T-T) rs4985534-rs11645214-rs6499323-rs7197333-rs1006985 0.39 0.27 1.74 (1.63-1.86) 4.72E-05 1.85 (1.74-1.97) 9.85E-06
H-freq: haplotype frequency.
aOnly crude p-value <10−4 was presented.
bA haplotype with a frequency of >0.05 was included in the analysis.
cp-value from logistic regression.
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(Additional file 1: Table S5).
The subjects in this study were a portion of the cohort
studied in a published GWAS paper [15]. Although the
sample size in this study was limited, the DN cases and
the controls were much more homogeneous in terms of
gender, age, durations of diabetes, and HbA1c level after
excluding subjects with extreme characteristics and
matching their age and durations of diabetes. A previous
study found that the Han Chinese residing in Taiwan
were relatively homogenous in genetic background,
spread among the three major ethnic groups of Minnan,
Hakka, and Mainland Chinese [50], which is consistent
with the results of our population stratification analysis.
Therefore, the impact of population stratification on our
genetic association study is small.
Conclusions
We identified 3 novel SNPs (rs11647932, rs11645214,
and rs6499323) and 11 haplotypes (4, 3, and 4 in win-
dow size of 3-SNP, 4-SNP, and 5-SNP, respectively), lo-
cated at the 16q22.1 region, that are susceptibility
variants of DN in a Han Chinese population in Taiwan.
The findings reveal that the susceptibility variants lo-
cated at the 16q22.1 region may involve in the biological
pathways of DN in Han Chinese patients with type 2
diabetes. Our results can provide new insights into the
etiology of DN.
Additional file
Additional file 1: Figure S1. Regional plot of these 11 SNPs located on
chromosome 16q22.1. The –log10 (p-value) (left y-axis) was from the trend
test using our data. The estimated r2 and recombination rate (right y-axis)
based on the HapMap Phase II JPT + CHB populations were plotted to
reflect the LD structure. The gene information was from the UCSC (Build
hg18). The regional plot was plotted from the LocusZoom, a web-based
plotting tool (csg.sph.umich.edu/locuszoom). Table S1. Summary of
identified polymorphisms through GWAS. Table S2. Summary of variants
associated with nephropathy in Han Chinese patients with type 2
diabetes through candidate gene approach. Table S3. is-rSNP prediction
resultsa. Table S4. Gene expression from human diabetic nephropathy
datasets in the Nephromine database. Table S5. Gene expression from
Hodgin Diabetes Mouse dataseta in the Nephromine database [51-63].
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